Table 3.
Premenopausal androgens and SHBG and breast cancer risk: Nurses' Health Study II, 1999 to 2009
| 1st Quintile | 2nd Quintile | 3rd Quintile | 4th Quintile | 5th Quintile | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | P trend | |
| Testosterone | ||||||
| Cutpoints, ng/dL | < 19 | ≥ 19 to 22.9 | ≥ 23 to 27.9 | ≥ 28 to 34.9 | ≥ 35 | |
| No. cases/No. controls* | 126/259 | 122/244 | 107/246 | 118/240 | 150/256 | |
| All cancers | 1.0 (referent) | 1.0 (0.7 to 1.4) | 0.9 (0.6 to 1.2) | 0.9 (0.7 to 1.3) | 1.2 (0.9 to 1.7) | 0.32 |
| Invasive | 1.0 (referent) | 1.2 (0.8 to 1.7) | 1.0 (0.7 to 1.4) | 0.9 (0.6 to 1.3) | 1.4 (1.0 to 2.0) | 0.23 |
| ER+/PR+ | 1.0 (referent) | 1.5 (1.0 to 2.3) | 1.1 (0.7 to 1.8) | 1.0 (0.6 to 1.5) | 1.7 (1.1 to 2.6) | 0.10 |
| In situ | 1.0 (referent) | 0.9 (0.5 to 1.5) | 0.9 (0.5 to 1.5) | 1.2 (0.7 to 1.9) | 1.0 (0.6 to 1.7) | 0.64 |
| Free testosterone | ||||||
| Cutpoints, ng/dL | < 0.14 | ≥ 0.14 to 0.179 | ≥ 0.18 to 0.239 | ≥ 0.24 to 0.309 | ≥ 0.31 | |
| No. cases/No. controls | 130/248 | 108/246 | 137/249 | 100/246 | 142/248 | |
| All cancers | 1.0 (referent) | 0.8 (0.6 to 1.1) | 1.0 (0.7 to 1.4) | 0.8 (0.6 to 1.1) | 1.1 (0.8 to 1.5) | 0.61 |
| Invasive | 1.0 (referent) | 0.9 (0.6 to 1.3) | 1.1 (0.8 to 1.6) | 0.9 (0.6 to 1.3) | 1.1 (0.8 to 1.6) | 0.49 |
| ER+/PR+ | 1.0 (referent) | 1.0 (0.6 to 1.5) | 1.1 (0.7 to 1.7) | 1.0 (0.6 to 1.5) | 1.5 (1.0 to 2.2) | 0.09 |
| In situ | 1.0 (referent) | 0.9 (0.6 to 1.6) | 1.1 (0.7 to 1.8) | 0.7 (0.4 to 1.3) | 1.3 (0.8 to 2.1) | 0.47 |
| DHEAS | ||||||
| Cutpoints, μg/dL | < 55 | ≥ 55 to 76.9 | ≥ 77 to 100.9 | ≥ 101 to 135.9 | ≥ 136 | |
| No. cases/No. controls | 123/249 | 96/253 | 136/250 | 146/251 | 127/251 | |
| All cancers | 1.0 (referent) | 0.8 (0.5 to 1.1) | 1.1 (0.8 to 1.6) | 1.2 (0.9 to 1.6) | 1.0 (0.7 to 1.4) | 0.30 |
| Invasive | 1.0 (referent) | 0.8 (0.5 to 1.1) | 1.1 (0.8 to 1.6) | 1.1 (0.8 to 1.6) | 1.1 (0.7 to 1.5) | 0.29 |
| ER+/PR+ | 1.0 (referent) | 0.9 (0.5 to 1.4) | 1.4 (0.9 to 2.2) | 1.5 (1.0 to 2.2) | 1.3 (0.8 to 2.0) | 0.05 |
| In situ | 1.0 (referent) | 0.8 (0.5 to 1.4) | 1.0 (0.6 to 1.7) | 1.3 (0.8 to 2.2) | 0.9 (0.5 to 1.6) | 0.62 |
| SHBG | ||||||
| Cutpoints, nmol/mL | < 40 | ≥ 40 to 54.9 | ≥ 55 to 70.9 | ≥ 71 to 91.9 | ≥ 92 | |
| No. cases/No. controls | 110/253 | 117/245 | 131/249 | 136/249 | 130/250 | |
| All cancers | 1.0 (referent) | 1.1 (0.8 to 1.5) | 1.2 (0.8 to 1.6) | 1.2 (0.9 to 1.7) | 1.2 (0.8 to 1.6) | 0.23 |
| Invasive | 1.0 (referent) | 1.2 (0.8 to 1.8) | 1.4 (1.0 to 2.0) | 1.3 (0.9 to 1.9) | 1.3 (0.9 to 1.9) | 0.13 |
| ER+/PR+ | 1.0 (referent) | 1.1 (0.7 to 1.7) | 1.3 (0.8 to 2.0) | 1.3 (0.9 to 2.0) | 1.2 (0.8 to 1.8) | 0.35 |
| In situ | 1.0 (referent) | 0.8 (0.5 to 1.4) | 0.9 (0.5 to 1.5) | 1.0 (0.6 to 1.7) | 0.8 (0.5 to 1.4) | 0.72 |
All cancers: Conditional logistic regression for all cancers controlling for age at menarche, parity/age at first birth, BMI at age 18, family history of breast cancer, history of benign breast disease. Invasive, ER+/PR+, in situ tumors: Unconditional logistic regression for invasive, ER+/PR+, and in situ disease controlling for factors listed above and matching factors. *No. cases/No. controls are for all cancers; Overall No. cases/No. controls for invasive and ER+/PR+ cancers are in Table 4.